JP2011523645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523645A5 JP2011523645A5 JP2011510694A JP2011510694A JP2011523645A5 JP 2011523645 A5 JP2011523645 A5 JP 2011523645A5 JP 2011510694 A JP2011510694 A JP 2011510694A JP 2011510694 A JP2011510694 A JP 2011510694A JP 2011523645 A5 JP2011523645 A5 JP 2011523645A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- foregoing
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 187
- 150000003839 salts Chemical class 0.000 claims description 105
- 239000012453 solvate Substances 0.000 claims description 104
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 43
- 150000001413 amino acids Chemical group 0.000 claims description 38
- 229960005489 paracetamol Drugs 0.000 claims description 23
- URNSECGXFRDEDC-UHFFFAOYSA-N N-acetyl-1,4-benzoquinone imine Chemical compound CC(=O)N=C1C=CC(=O)C=C1 URNSECGXFRDEDC-UHFFFAOYSA-N 0.000 claims description 20
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 16
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 208000002193 Pain Diseases 0.000 claims description 15
- 206010037660 Pyrexia Diseases 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 208000037906 ischaemic injury Diseases 0.000 claims description 15
- 208000028389 Nerve injury Diseases 0.000 claims description 14
- 230000008764 nerve damage Effects 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 235000006109 methionine Nutrition 0.000 claims description 8
- 229930182817 methionine Chemical group 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical group CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims description 6
- 150000001944 cysteine derivatives Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 6
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 6
- -1 5-thiazolidinonyl Chemical group 0.000 claims description 5
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000007686 hepatotoxicity Effects 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 4
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 150000002332 glycine derivatives Chemical group 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 125000003835 nucleoside group Chemical group 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 2
- ATOTUUBRFJHZQG-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol;8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(C)(N)CO.O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 ATOTUUBRFJHZQG-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 229940125717 barbiturate Drugs 0.000 claims description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 claims description 2
- 229960004587 carisoprodol Drugs 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 229960003529 diazepam Drugs 0.000 claims description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 2
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 claims description 2
- 229960005178 doxylamine Drugs 0.000 claims description 2
- 229960005293 etodolac Drugs 0.000 claims description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 231100000234 hepatic damage Toxicity 0.000 claims description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 2
- 229960000240 hydrocodone Drugs 0.000 claims description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 2
- 229960001410 hydromorphone Drugs 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960003406 levorphanol Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000008818 liver damage Effects 0.000 claims description 2
- 229960004391 lorazepam Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003793 midazolam Drugs 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- VTCDEJZIEHTNBC-UHFFFAOYSA-N n-(2,5-dioxocyclohex-3-en-1-ylidene)acetamide Chemical class CC(=O)N=C1CC(=O)C=CC1=O VTCDEJZIEHTNBC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 229960003357 pamabrom Drugs 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229960004380 tramadol Drugs 0.000 claims description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002546 butalbital Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims 1
- 229960005249 misoprostol Drugs 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 231100000816 toxic dose Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- OCWJVIUDOHXKHI-PWNUKQCCSA-N methyl 7-[(1r,2s)-2-[(e)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopent-3-en-1-yl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)OC OCWJVIUDOHXKHI-PWNUKQCCSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5477708P | 2008-05-20 | 2008-05-20 | |
| US61/054,777 | 2008-05-20 | ||
| PCT/US2009/044749 WO2009143299A1 (en) | 2008-05-20 | 2009-05-20 | Hepatoprotectant acetaminophen mutual prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014018474A Division JP2014111632A (ja) | 2008-05-20 | 2014-02-03 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523645A JP2011523645A (ja) | 2011-08-18 |
| JP2011523645A5 true JP2011523645A5 (enExample) | 2012-07-05 |
| JP5701750B2 JP5701750B2 (ja) | 2015-04-15 |
Family
ID=41340540
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510694A Expired - Fee Related JP5701750B2 (ja) | 2008-05-20 | 2009-05-20 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2014018474A Withdrawn JP2014111632A (ja) | 2008-05-20 | 2014-02-03 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2015180278A Withdrawn JP2015227384A (ja) | 2008-05-20 | 2015-09-14 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2017140812A Withdrawn JP2017186380A (ja) | 2008-05-20 | 2017-07-20 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2019034258A Withdrawn JP2019081793A (ja) | 2008-05-20 | 2019-02-27 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2020201931A Withdrawn JP2021036001A (ja) | 2008-05-20 | 2020-12-04 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014018474A Withdrawn JP2014111632A (ja) | 2008-05-20 | 2014-02-03 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2015180278A Withdrawn JP2015227384A (ja) | 2008-05-20 | 2015-09-14 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2017140812A Withdrawn JP2017186380A (ja) | 2008-05-20 | 2017-07-20 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2019034258A Withdrawn JP2019081793A (ja) | 2008-05-20 | 2019-02-27 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
| JP2020201931A Withdrawn JP2021036001A (ja) | 2008-05-20 | 2020-12-04 | 肝保護剤アセトアミノフェンミューチュアルプロドラッグ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20110263545A1 (enExample) |
| EP (1) | EP2285419A4 (enExample) |
| JP (6) | JP5701750B2 (enExample) |
| KR (1) | KR101717145B1 (enExample) |
| CN (1) | CN102149412A (enExample) |
| AU (1) | AU2009249071A1 (enExample) |
| BR (1) | BRPI0912820A2 (enExample) |
| CA (2) | CA2724788C (enExample) |
| IL (1) | IL209384A0 (enExample) |
| MX (1) | MX2010012647A (enExample) |
| RU (1) | RU2010151951A (enExample) |
| WO (1) | WO2009143299A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2285419A4 (en) | 2008-05-20 | 2012-05-02 | Neurogesx Inc | LUBRICANT MUTUAL PARACETAMOL PRODRUGS |
| CA2724877C (en) | 2008-05-20 | 2016-09-13 | Neurogesx, Inc. | Water-soluble acetaminophen analogs |
| KR101677126B1 (ko) * | 2008-05-20 | 2016-11-22 | 노이로제스엑스, 인코포레이티드 | 탄산염 프로드러그 및 그것의 사용 방법 |
| JP6029670B2 (ja) | 2011-09-22 | 2016-11-24 | アコーダ セラピューティクス、インク． | アセトアミノフェンコンジュゲートおよびその組成物ならびにその使用方法 |
| US20140179615A1 (en) * | 2012-07-12 | 2014-06-26 | Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. | Glutathione and Acetaminophen Composition and Preparation Method Thereof |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US20170246194A1 (en) * | 2014-08-15 | 2017-08-31 | Purdue Pharma L.P. | Acetaminophen-Containing Analgesic Formulations With Reduced Hepatotoxicity |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| US11389409B2 (en) * | 2019-08-30 | 2022-07-19 | Remedy Diagnostics LLC | Transdermal device comprising acetaminophen prodrug |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035507A (en) * | 1975-04-17 | 1977-07-12 | Interx Research Corporation | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease |
| GB1583602A (en) * | 1977-05-26 | 1981-01-28 | Sterwin Ag | N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives |
| US4562024A (en) | 1982-07-06 | 1985-12-31 | Sterling Drug Inc. | Process for preparing granulate containing poorly compressible medicinally active matter |
| CH654302A5 (de) * | 1983-05-04 | 1986-02-14 | Sandoz Ag | Acylaminophenolderivate, ihre herstellung und arzneimittel, welche sie enthalten. |
| US5001115A (en) * | 1989-05-17 | 1991-03-19 | University Of Florida | Prodrugs of biologically active hydroxyaromatic compounds |
| US5474757A (en) * | 1992-10-16 | 1995-12-12 | Rutgers University | Prevention of acetaminophen overdose toxicity with organosulfur compounds |
| DE4327462A1 (de) * | 1993-08-16 | 1995-02-23 | Carl Heinrich Dr Weischer | Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen |
| US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
| US6710086B1 (en) | 2000-02-25 | 2004-03-23 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
| AU2001260113B2 (en) | 2000-03-14 | 2006-04-06 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivatives |
| AU4085201A (en) | 2000-03-15 | 2001-09-24 | Imperial College Innovations Limited | Pharmaceutical composition |
| IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
| US20030073618A1 (en) * | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| DE60239801D1 (de) | 2001-06-05 | 2011-06-01 | Control Delivery Systems Watertown | Analgetika mit verzögerter wirkstoffabgabe |
| EP1448231A1 (en) | 2001-11-19 | 2004-08-25 | Control Delivery Systems, Inc. | Topical delivery of codrugs |
| WO2003049804A2 (en) | 2001-12-10 | 2003-06-19 | Control Delivery Systems Inc. | Treatment of genitourinary tract disorders |
| US20050164994A1 (en) | 2001-12-10 | 2005-07-28 | Control Deliver Systems, Inc. | Treatment of genitourinary tract disorders |
| EP1465596A1 (en) | 2002-01-18 | 2004-10-13 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| US20040058946A1 (en) | 2002-07-05 | 2004-03-25 | Buchwald Stephen L. | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals |
| US7381721B2 (en) | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| KR101255074B1 (ko) | 2003-10-01 | 2013-04-16 | 아돌로 코포레이션 | 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법 |
| DE602004031301D1 (de) | 2003-11-12 | 2011-03-17 | Applied Nanosystems Bv | Nichtsymmetrisches geliermittel |
| US20050113294A1 (en) | 2003-11-21 | 2005-05-26 | Adolor Corporation. | Carboxamide and amino derivatives and methods of their use |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| US7598261B2 (en) | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| BRPI0613911A2 (pt) | 2005-07-27 | 2011-02-22 | Orexigen Therapeutics Inc | composições para afetar a perda de peso |
| PE20081192A1 (es) | 2006-03-24 | 2008-10-07 | Wyeth Corp | Tratamiento del dolor |
| CA2671737A1 (en) | 2006-12-05 | 2008-06-12 | Neurogesx, Inc. | Prodrugs and methods of making and using the same |
| EP2285419A4 (en) | 2008-05-20 | 2012-05-02 | Neurogesx Inc | LUBRICANT MUTUAL PARACETAMOL PRODRUGS |
| CA2724877C (en) | 2008-05-20 | 2016-09-13 | Neurogesx, Inc. | Water-soluble acetaminophen analogs |
| KR101677126B1 (ko) | 2008-05-20 | 2016-11-22 | 노이로제스엑스, 인코포레이티드 | 탄산염 프로드러그 및 그것의 사용 방법 |
-
2009
- 2009-05-20 EP EP09751527A patent/EP2285419A4/en not_active Withdrawn
- 2009-05-20 BR BRPI0912820A patent/BRPI0912820A2/pt not_active IP Right Cessation
- 2009-05-20 AU AU2009249071A patent/AU2009249071A1/en not_active Abandoned
- 2009-05-20 KR KR1020107028511A patent/KR101717145B1/ko not_active Expired - Fee Related
- 2009-05-20 CA CA2724788A patent/CA2724788C/en not_active Expired - Fee Related
- 2009-05-20 CN CN2009801282430A patent/CN102149412A/zh active Pending
- 2009-05-20 RU RU2010151951/15A patent/RU2010151951A/ru not_active Application Discontinuation
- 2009-05-20 JP JP2011510694A patent/JP5701750B2/ja not_active Expired - Fee Related
- 2009-05-20 US US12/993,091 patent/US20110263545A1/en not_active Abandoned
- 2009-05-20 CA CA2946445A patent/CA2946445C/en not_active Expired - Fee Related
- 2009-05-20 MX MX2010012647A patent/MX2010012647A/es active IP Right Grant
- 2009-05-20 WO PCT/US2009/044749 patent/WO2009143299A1/en not_active Ceased
-
2010
- 2010-11-17 IL IL209384A patent/IL209384A0/en unknown
-
2014
- 2014-02-03 JP JP2014018474A patent/JP2014111632A/ja not_active Withdrawn
-
2015
- 2015-09-14 JP JP2015180278A patent/JP2015227384A/ja not_active Withdrawn
-
2016
- 2016-05-09 US US15/150,099 patent/US9951001B2/en active Active
-
2017
- 2017-07-20 JP JP2017140812A patent/JP2017186380A/ja not_active Withdrawn
-
2018
- 2018-03-15 US US15/922,273 patent/US20190062273A1/en not_active Abandoned
-
2019
- 2019-02-27 JP JP2019034258A patent/JP2019081793A/ja not_active Withdrawn
-
2020
- 2020-12-04 JP JP2020201931A patent/JP2021036001A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523645A5 (enExample) | ||
| RU2010151951A (ru) | Общие пролекарства гепатопротектора и ацетаминофена | |
| JP2011520977A5 (enExample) | ||
| ES2670407T3 (es) | Profármacos de acetaminofén solubles en agua cargados positivamente y compuestos relacionados con una tasa de penetración de la piel muy rápida | |
| CN102216257B (zh) | Gaba偶联物及其使用方法 | |
| RU2010151952A (ru) | Водорастворимые аналоги ацетаминофена | |
| ES2754221T3 (es) | Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo | |
| JP2009538348A5 (enExample) | ||
| JP2013503862A5 (enExample) | ||
| ES2325163T3 (es) | Compuestos analgesicos, su sintesis y composiciones farmaceuticas que los contienen. | |
| JP2009526865A5 (enExample) | ||
| JP2014532728A5 (enExample) | ||
| JP2013500304A5 (enExample) | ||
| CA3018821C (en) | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas | |
| BRPI0605921B1 (pt) | Compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
| HRP20141120T1 (hr) | Furazanobenzimidazoli kao predlijekovi za lijeäśenje neoplastiäśnih ili autoimunih bolesti | |
| JP2011006428A5 (enExample) | ||
| RU2007136535A (ru) | Пептидомиметические соединения и получение биологически активных производных | |
| JP6223995B2 (ja) | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 | |
| JP2007505044A5 (enExample) | ||
| RU2000125889A (ru) | Замещенные бисиндолималеимиды, предназначенные для ингибирования пролиферации клеток | |
| ES2770362T3 (es) | Bencenopropanamida N-sustituida para su uso en el tratamiento del dolor y la inflamación | |
| JP2005501121A5 (enExample) | ||
| EP4051269A1 (en) | D-amphetamine compounds, compositions, and processes for making and using the same | |
| JP2011502985A5 (enExample) |